Q-omics provides the consensus-scored HTR7 profile across patient tissues and cancer cell-line models. HTR7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HTR7 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, HTR7 RNA expression shows 18,236 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, COAD, and UVM as cancer lineages where HTR7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR7 survival associations across molecular data types. HTR7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR7 RNA expression–survival associations across cancer types. High HTR7 expression shows unfavorable associations in UVM, LAML, HNSC and STAD, but favorable associations in KIRC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HTR7 RNA expression.
This table summarizes HTR7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HTR7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR7 shows lower tumor expression in COAD, STAD and READ and higher tumor expression in HNSC, KIRC and LUSC. The COAD box plot shows higher HTR7 RNA expression in normal versus tumor tissue (log2 FC = −1.080, t-test p < 0.001).
This table shows molecular features associated with HTR7 in patient tissues and cancer cell lines. In patient samples, HTR7 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
